Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study - Université Pierre et Marie Curie Accéder directement au contenu
Article Dans Une Revue Neurology Année : 2016

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study

1 CIC Nantes - Centre d’Investigation Clinique de Nantes
2 Biostatistique, Pharmacoépidémiologie et Mesures Subjectives en Santé
3 CIC - Centre d'Investigation Clinique [Rennes]
4 CarMeN - Cardiovasculaire, métabolisme, diabétologie et nutrition
5 ReLSEP
6 Department of Neurology
7 Service de Neurologie [Lyon]
8 CPTP - Centre de Physiopathologie Toulouse Purpan
9 Service de Neurologie
10 Service de neurologie [Bordeaux]
11 UB - Université de Bordeaux
12 Pôle de Neurosciences Cliniques, Department of Neurology
13 Inflammation: mécanismes et régulation et interactions avec la nutrition et les candidoses
14 EA 2686 - Laboratoire d'Immunologie
15 Service de neurologie D
16 VisAGeS - Vision, Action et Gestion d'informations en Santé
17 Department of Neurology
18 Department of Neurology
19 Service de Neurologie
20 Hôpital Maison Blanche
21 ICM - Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute
22 SHFJ - Service Hospitalier Frédéric Joliot
23 CHU Saint-Antoine [AP-HP]
24 Department of Neurology
25 CHU Pitié-Salpêtrière [AP-HP]
26 Department of Neurology
27 Service de Neurologie [CHRU Besançon]
28 Service de Neurologie [CHU de Poissy]
29 Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon)
30 Service de Neurologie
31 ENT - Excitabilité nerveuse et thérapeutique
32 CRMBM - Centre de résonance magnétique biologique et médicale
33 CHU Limoges
34 Service de Neurologie [CHU Caen]
35 Biostatistique, Recherche Clinique et Mesures Subjectives en Santé
36 U1064 Inserm - CRTI - Centre de Recherche en Transplantation et Immunologie
Marc Debouverie
  • Fonction : Auteur
  • PersonId : 762777
  • IdRef : 068986629
Sandra Vukusic
Christine Lebrun-Frenay
Eric Thouvenot
Jean-Philippe Camdessanché
Caroline Papeix
Olivier Gout
  • Fonction : Auteur
  • PersonId : 946000
  • IdRef : 052535118
Laurent Magy
  • Fonction : Auteur

Résumé

OBJECTIVE: To compare natalizumab and fingolimod on both clinical and MRI outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) from 27 multiple sclerosis centers participating in the French follow-up cohort Observatoire of Multiple Sclerosis. METHODS: Patients with RRMS included in the study were aged from 18 to 65 years with an Expanded Disability Status Scale score of 0-5.5 and an available brain MRI performed within the year before treatment initiation. The data were collected for 326 patients treated with natalizumab and 303 with fingolimod. The statistical analysis was performed using 2 different methods: logistic regression and propensity scores (inverse probability treatment weighting). RESULTS: The confounder-adjusted proportion of patients with at least one relapse within the first and second year of treatment was lower in natalizumab-treated patients compared to the fingolimod group (21.1% vs 30.4% at first year, p = 0.0092; and 30.9% vs 41.7% at second year, p = 0.0059) and supported the trend observed in nonadjusted analysis (21.2% vs 27.1% at 1 year, p = 0.0775). Such statistically significant associations were also observed for gadolinium (Gd)-enhancing lesions and new T2 lesions at both 1 year (Gd-enhancing lesions: 9.3% vs 29.8%, p \textless 0.0001; new T2 lesions: 10.6% vs 29.6%, p \textless 0.0001) and 2 years (Gd-enhancing lesions: 9.1% vs 22.1%, p = 0.0025; new T2 lesions: 16.9% vs 34.1%, p = 0.0010) post treatment initiation. CONCLUSION: Taken together, these results suggest the superiority of natalizumab over fingolimod to prevent relapses and new T2 and Gd-enhancing lesions at 1 and 2 years. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with RRMS, natalizumab decreases the proportion of patients with at least one relapse within the first year of treatment compared to fingolimod
Fichier principal
Vignette du fichier
Neurology-2016-Barbin-771-8.pdf (433.04 Ko) Télécharger le fichier
Origine : Publication financée par une institution
Loading...

Dates et versions

hal-01299977 , version 1 (11-04-2016)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Laetitia Barbin, Chloé Rousseau, Natacha Jousset, Romain Casey, Marc Debouverie, et al.. Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. Neurology, 2016, 86 (8), pp.771-778. ⟨10.1212/WNL.0000000000002395⟩. ⟨hal-01299977⟩
1069 Consultations
326 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More